Immunomodulatory Effects of Fasting in Healthy Adults
Recruiting
This is a clinical trial assessing the effects of fasting on the immune system in healthy adults. Immune profiling, gene expression profiling, and flow cytometry on peripheral blood mononuclear cells (PBMCs) will be performed and we hypothesize that a period of fasting will alter the immune system in healthy adults.
Gender:
ALL
Ages:
Between 20 years and 40 years
Trial Updated:
03/27/2025
Locations: UC Davis, Sacramento, California
Conditions: Fasting
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
Recruiting
The goal of this proof-of-concept clinical trial is to determine whether cardiac rehabilitation improves exercise capacity and chronotropic (heart rate) response to exercise among people with Long COVID. The study will include individuals with confirmed SARS-CoV-2 infection, symptoms not present prior to COVID-19 that are persistent for at least 3 months after acute infection ("Long COVID"), and who have reduced exercise capacity less than predicted and reduced heart rate response during cardiop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Long COVID, COVID-19
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Clinical Innovations, Inc., Bellflower, California +85 locations
Conditions: Treatment Resistant Depression
CANF-Comb-II PET-MR in Atherosclerosis Multisite
Recruiting
The goal of this observational study is to learn more about plaque biology in asymptomatic carotid artery stenosis (ACAS) patients through imaging. The main questions it aims to answer are: * To determine the ability of 64Cu-CANF-Comb positron emission tomography (PET) to risk stratify ACAS patients for stroke event, to include transient ischemic attack or remote ipsilateral intervention. * To further understand the role of Natriuretic Peptide Receptor C (NPRC) in the evolution of carotid ather... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Cedars Sinai Medical Center, Los Angeles, California +1 locations
Conditions: Carotid Atherosclerosis, Asymptomatic Carotid Artery Stenosis, Carotid Artery Atheroma
A Mixed Methods Pilot Trial of the STEP Home Workshop to Improve Reintegration and Reduce Suicide Risk for Recently Transitioned Veterans
Recruiting
Risk of Veteran suicide is elevated during the first year of transition from military service to civilian life. Most Veteran suicides occur among Veterans who are not connected to VA healthcare. Suicide prevention and connection to care are therefore critical for recently transitioning Veterans. Transitioning Veterans require services to provide them with suicide prevention education, skills to manage their transition effectively, and support in their access to VA healthcare. Convenient, accessi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/27/2025
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: TBI, Suicide Prevention, Veterans, PTSD, Transdiagnostic, Anger
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Recruiting
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +169 locations
Conditions: Metastatic Urothelial Cancer
Optimizing a Digital AEP Risk Intervention With Native Women and Communities
Recruiting
The purpose of AIM 1 of the study is to gather quantitative and qualitative information to inform the development of a digital app tailored for Native American women to help them avoid a pregnancy affected by alcohol.
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
03/27/2025
Locations: University of Virginia Fontaine Research Park, Charlottesville, Virginia
Conditions: Alcohol Exposed Pregnancy, Alcohol Use, Unspecified, Contraception Use, Sexual Behavior, Unplanned Pregnancy
GLP-1R Agonist Treatment for Opioid Use Disorder
Recruiting
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semagl... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2025
Locations: University of Maryland Baltimore, Baltimore, Maryland +2 locations
Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
POMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment
Recruiting
This multi-centered, randomized controlled trial will evaluate the safety and efficacy of home use of the novel Reia System (RS), which includes the Reia pessary and applicator, compared to standard pessary care (Gellhorn or ring with/without support without knob) among women with stage II-IV pelvic organ prolapse (POP). A total of 182 participants will be recruited among pessary naïve patients who are symptomatic and choose a vaginal pessary for management of their POP from study sites speciali... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +7 locations
Conditions: Pelvic Organ Prolapse, Prolapse
Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Recruiting
This is a Phase III, multisite, randomized, double-blinded study to investigate BNT327 combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Clermont Oncology Center, Clermont, Florida +8 locations
Conditions: Extensive-stage Small-cell Lung Cancer
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Recruiting
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Dana Farber/Massachusetts General Hospital, Inc, Boston, Massachusetts +4 locations
Conditions: Solid Tumor
Multi-omics Study in Citrin Deficiency
Recruiting
Citrin deficiency (CD) is an underdiagnosed and understudied condition characterized by several distinct phenotypes: 1) neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), 2) the adaptation or silent period, 3) "failure to thrive and dyslipidemia" form of CD (FTTDCD), and 4) citrullinemia type II (CTLN2), with the latter representing the final and most severe form of the condition. There is currently no cure for CD and patients manage their symptoms with lifelong dietary inter... Read More
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
03/27/2025
Locations: Mount Sinai Hospital, New York, New York +22 locations
Conditions: Citrin Deficiency